DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

The Westin Arlington

2025 年 04 月 07 日 7:00 上午 - 2025 年 04 月 08 日 4:00 下午

801 N. Glebe Road, Arlington, VA 22203, USA

Global Labeling Conference

Join speakers from around the world sharing their labeling expertise!

Early Bird Rates Expire

DAYS

HOURS

MINUTES

SECONDS

Session 9: Rare Diseases: Cell and Gene Therapy Labeling Requirements and Considerations

Session Chair(s)

Hayley  Parker, PhD, MSc

Hayley Parker, PhD, MSc

Senior Vice President

Pepgen Inc., United States

Cell and Gene Therapies (CGT) are increasingly being used to develop novel treatments for rare diseases. Recently there has been a plethora of guidelines to aid the development of CGT, which ultimately can impact the end-label. Labeling professionals should be aware of these emerging guidelines, as well as the standard labeling guidelines, to optimize the development and life-cycle management of labels for CGTs. Unique situations, challenges, and requirements face CGTs which require the labeling team to engage with a broad stakeholder network during development. Considerations include safety concerns associated with CGTs (including benefit-risk considerations for specific populations), the types of nonclinical studies to be performed to support clinical trials, the study expectations and design elements, alternative endpoints/data sets informing the label, traceability, and planning of long-term follow-up requirements and supply chain. This session will focus on some case studies, examples, and considerations where factoring in these broader elements of labeling to successfully optimize the use of CGTs products in rare disease.

Learning Objective :
  • Understand some of the unique labeling requirements for Rare Diseases treated with CGT
  • Identify additional stakeholders which may be required for labeling development and life-cycle management for Rare Diseases treated with CGT, including the patient perspective
  • Discuss best practices for supporting label development and life cycle management for Rare Diseases treated with CGT

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。